A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer - United Kingdom
doi 10.1186/s12885-017-3143-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

Phase I Dose‐escalation Study of Volasertib in Pediatric Patients With Acute Leukemia or Advanced Solid Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors

Oncologist
Cancer ResearchMedicineOncology
2017English

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2013English

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

Phase I Dose-Escalation Study of Copanlisib in Combination With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy